A comparative study based on ainuovirine/lamivudine/tenofovir against HIV-1

Background Ainuovirine, as a third-generation non-nucleoside reverse transcriptase inhibitor against HIV-1, is widely used in China. To evaluate its therapeutic efficacy and disadvantages, a comparative study based on Ainuovirine had been conducted. Method We investigated 199 people living with HIV-...

Full description

Saved in:
Bibliographic Details
Published in:International journal of STD & AIDS 2024-12, Vol.35 (14), p.1103-1111
Main Authors: Luo, Peipei, Jin, Juan, Li, Jiajia, Yin, Jinling, Jing, Xinyan, Hou, Haohua, Ba, Huanhuan, Zhang, Yuan
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Ainuovirine, as a third-generation non-nucleoside reverse transcriptase inhibitor against HIV-1, is widely used in China. To evaluate its therapeutic efficacy and disadvantages, a comparative study based on Ainuovirine had been conducted. Method We investigated 199 people living with HIV-1 who received Ainuovirine (ANV)/lamivudine/tenofovir and 202 people living with HIV-1 who received Efavirenz (EFV)/lamivudine/tenofovir. Results After 48 weeks of therapy, ANV and EFV showed similar viral inhibitory effects. However, in the ANV group, more participants had CD4/CD8 ratios restored to the normal range, lower levels of triglycerides and low-density lipoprotein, relatively normal liver alanine aminotransferase, and fewer adverse events. Conclusion Therefore, due to its role in immune reconstitution, dyslipidemia, and safety, ANV may be a recommended option for people living with HIV-1.
ISSN:0956-4624
1758-1052
1758-1052
DOI:10.1177/09564624241282366